For research and educational purposes only. Not medical advice.
Ertugliflozin Reference
Educational, not medical advice reference for Ertugliflozin: Metabolic; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
VERTIS CV (Cannon 2020 NEJM, n=8,246 adults with T2D and established atherosclerotic cardiovascular disease) reported non-inferiority versus placebo for the primary 3-component MACE composite but did not demonstrate superiority. The renal composite and heart-failure-hospitalization secondary endpoints did not reach statistical significance after hierarchical testing. This positions ertugliflozin differently from empagliflozin, dapagliflozin, and canagliflozin in class-comparative cardiovascular discussions.
Regulatory and posture
- Categories
- Metabolic
- Aliases
- Steglatro, SGLT2 inhibitor (small molecule, not a peptide)
- Evidence posture
- human - VERTIS CV demonstrated non-inferiority but not superiority for MACE - the only SGLT2 outcome trial that did not show superior CV outcomes versus placebo.
- Regulatory status
- FDA-approved as Steglatro (2017) for type 2 diabetes as an adjunct to diet and exercise. Fixed-dose combinations with sitagliptin (Steglujan) and metformin (Segluromet) are also approved.
- Content review status
- label verified